Product Information

BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE is a generic product labeled by Sunrise Pharmaceutical Inc., priced at $0.3526 per EA under NDC 11534018701. Its NADAC has been published 488 times since Jul 12, 2017.

FDA first approved this application on Oct 28, 2016. Its Orange Book therapeutic-equivalence code is AA.

BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE

butalbital, acetaminophen and caffeine
$0.3526per EA
DEA Schedule CIII

Strength

300; 50; 40 mg/1; mg/1; mg/1

NDC

11534018701

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA207118

FDA Approved

10/28/2016

TE Code

AA

On Market Since

1/10/2017

Pharmacological Classes

Barbiturate
Barbiturates
Central Nervous System Stimulant
Central Nervous System Stimulation
Methylxanthine
Xanthines

Price Statistics

The NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE has been published 488 times since Jul 12, 2017, and over the history we have for it it has declined 84.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.3526 per EA
All-time high$2.3602 (Aug 16, 2017)
All-time low$0.3110 (Apr 22, 2026)
52-week high$0.3526
52-week low$0.3110
Median price$0.6461
Average price$1.0155
Largest weekly change+34.5% (Jun 19, 2024)
Weeks tracked488
Tracking sinceJul 12, 2017

Price History

1W

0.0%

1M

+11.5%

3M

+10.2%

6M

+13.4%

1Y

+2.9%

3Y

-41.1%

5Y

-44.1%

All

-84.9%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE, manufactured by Sunrise Pharmaceutical Inc., is $0.3526 per EA (NDC 11534018701), effective Nov 11, 2026.

How has the price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE has declined 84.9%. It has been tracked across 488 weekly CMS publications since Jul 12, 2017.

What are the highest and lowest recorded NADAC prices for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE?

Since Jul 12, 2017, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE has ranged from a low of $0.3110 (Apr 22, 2026) to a high of $2.3602 (Aug 16, 2017), with a median of $0.6461 per EA.

Are there cheaper alternatives to BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE?

2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE in a comparable dosage form, but none are currently priced below it.

Who manufactures BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE?

BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE (NDC 11534018701) is labeled by Sunrise Pharmaceutical Inc., and CMS classifies it as a generic product.